Driving T1D Innovation Forward

The Bukhman Foundation is contributing $12 million to the T1D Fund to accelerate cure-oriented therapies and drive the next wave of innovation in T1D.

The Fund works closely with Breakthrough T1D (formerly JDRF) and the Leona M. and Harry B. Helmsley Charitable Trust, supporting research, innovation, and the global T1D community.

This milestone builds on our ongoing commitment with Diabetes UK, Breakthrough T1D, and the Bukhman Centre for Research Excellence in T1D at the University of Oxford, reflecting our dedication to collaboration and science for a future where type 1 no longer limits lives.

About the T1D Fund
Launched in 2016, the T1D Fund is the first scaled venture fund established to catalyze the development of T1D cure-oriented therapies through equity investments. The Fund co-invests with venture capital and biopharma in support of early-stage companies pursuing disease modifying therapies and potential cures for T1D. A core element of our mission is to rapidly advance promising therapies through development and ultimately regulatory approval. The Fund works in close partnership with Breakthrough T1D (formerly JDRF) and The Leona M. and Harry B. Helmsley Charitable Trust—two of the leading global organizations committed to supporting the T1D community and to advancing T1D research and innovation. Led by a deeply experienced team of healthcare and investing professionals, the Fund leverages its vast research, clinical, regulatory and medical affairs network on behalf of its portfolio companies. Capitalized through philanthropic dollars, the Fund makes investments in biotech companies and recycles returns into new investments, thereby extending the impact of its donors’ contributions.